Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) (Q57908992)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) |
article |
Statements
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) (English)
Masahiro Fukuoka
Sumitra Thongprasert
Patrapim Sunpaweravong
Swan-Swan Leong
Virote Sriuranpong
Tsu-Yi Chao
Kazuhiko Nakagawa
Da-Tong Chu
Nagahiro Saijo
Yuri Rukazenkov
Georgina Speake
Haiyi Jiang
Emma L Duffield
Alison A Armour